HK Stock MarketDetailed Quotes

02160 CARDIOFLOW-B

Watchlist
  • 1.130
  • +0.070+6.60%
Market Closed Mar 28 16:08 CST
2.73BMarket Cap-5231P/E (TTM)

About CARDIOFLOW-B Company

We are a medical device company focusing on the development and commercialization of innovative catheterization and surgical solutions in the field of structural heart disease. We are deeply involved in a large-scale, rapidly growing medical device market for structural heart disease with a serious lack of penetration. We have a comprehensive structural heart disease product pipeline layout, and are actively exploring external cooperation to accelerate the promotion of the popularity and reputation of the structural heart disease field on a global scale. Our mission Our mission is to provide accessible, honest, and comprehensive medical solutions for the treatment of structural heart disease. Our vision Our vision is to build a leading global emerging high-tech healthcare group centered on people. Product pipelines We have established a comprehensive innovative product line covering TAVI products, TMV products, TTV products, surgical valve products and surgical ancillary products, and are committed to providing physicians and patients with a true, friendly, and comprehensive medical solution for treating structural heart disease.

Company Profile

Symbol02160
Company NameCARDIOFLOW-B
ISINKYG6082P1054
Listing Date02/04/2021
Issue Price12.20
Shares Offered205.62M share
Founded01/10/2019
RegistrationCayman Islands
ChairmanGuoming Chen
SecretaryXiangmei\chenluoer Li
Audit InstitutionKPMG
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeThird Floor, Century Yard, Cricket Square, P.O. Box 902, Grand Cayman, KY1-1103, Cayman Islands
Head Office and Principal Place of BusinessRoom 1901, 19th floor, Lee Garden Phase I, 33 Hysan Avenue, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees592
MarketHong Kong motherboard
Phone(86)(21)38954600
Fax(86)(21)50801305
Emailwcxt@microport.com
Business Minimally Invasive Xintong Medical Technology Co., Ltd. is a Chinese investment holding company mainly engaged in the medical device industry. The company is mainly engaged in the development and commercialization of transcatheter and surgical solutions in the field of valvular heart disease. The company's main products include the first-generation transcatheter aortic valve implant (TAVI) product “VitaFlow” and the second-generation TAVI product “VitaFlow II.” The company mainly operates in the domestic market.

Company Executives

  • Name
  • Position
  • Salary
  • Jeffrey R Lindstrom
  • Director and General Manager of Shanghai Minimally Invasive,Executive Director,President
  • --
  • Guoming Chen
  • Chairman of Shanghai Minimally Invasive Heart Connect,Chairman,Nomination Committee Chairman,Remuneration Committee Member,Authorized Representative,Non-Executive Director
  • --
  • Luying Yan
  • Vice President (Regulatory Affairs and Clinical Trials),Executive Director
  • --
  • Liang Zhao
  • Senior VP,Executive Director
  • --
  • Junjie Zhang
  • Non-Executive Director
  • --
  • Xia Wu
  • Non-Executive Director
  • --
  • Jiahong Zhou
  • Audit Committee Chairman,Remuneration Committee Member,Independent Non-Executive Director
  • --
  • Zhixiang Sun
  • Independent Non-Executive Director,Remuneration Committee Chairman,Audit Committee Member,Nomination Committee Member
  • --
  • Jiandong Ding
  • Audit Committee Member,Independent Non-Executive Director,Nomination Committee Member
  • --
  • Xiangmei Li
  • Joint Company Secretary
  • --
  • Luoer Chen
  • Joint Company Secretary,Authorized Representative
  • --
  • Jeff Lindstrom
  • Vice President (Research and Development)
  • --
  • Nuan Ni
  • Senior Director of Finance
  • --
  • Wei Sun
  • Senior Director of Supply Chain
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg